



# LUND UNIVERSITY

## The mechanism of protein kinase C regulation

Kazi, Julhash U.

*Published in:*  
Frontiers in Biology

2011

[Link to publication](#)

*Citation for published version (APA):*

Kazi, J. U. (2011). The mechanism of protein kinase C regulation. *Frontiers in Biology*, 6(4), 328-336.  
<http://link.springer.com/article/10.1007/s11515-011-1070-5>

*Total number of authors:*

1

### General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117  
221 00 Lund  
+46 46-222 00 00



This is an author produced version of a paper published in “**Frontiers in Biolog**”

**Citation information:** Kazi J. U. (2011) The mechanism of protein kinase C regulation. *Frontiers in Biology* 6(4), 328-336

**Link to the original article:** <http://link.springer.com/article/10.1007/s11515-011-1070-5>

## **The mechanism of protein kinase C regulation**

Julhash U. Kazi

Laboratory of Computational Biochemistry, KN Biomedical Research Institute, Bagura Road,

Barisal, Bangladesh.

Quality Control Section, Opsonin Pharma Ltd, Bagura Road, Barisal, Bangladesh.

### **\* Corresponding author**

Julhash U. Kazi

Quality Control Section, OPSONIN Pharma Ltd.

Bagura Road, Barisal-8200, Bangladesh

Tel. +880-431-64074, Fax. +880-431-64075,

E-mail. lcb.kazi@gmail.com

### **Keywords:**

PKC, Biochemistry, PKC kinase, PKC substrate, PKC phosphatases, PKC structure.

## **Abstract**

Protein kinase C (PKC) is a family of serine/threonine protein kinases that plays a central role in transducing extracellular signals into a variety of intracellular responses ranging from cell proliferation to apoptosis. Nine PKC genes have been identified in the human genome, which encode 10 proteins. Each member of this protein kinase family displays distinct biochemical characteristics and is enriched in different cellular and subcellular locations. Activation of PKC has been implicated in the regulation of cell growth and differentiation. This review summarizes works of the past years in the field of PKC biochemistry that covers regulation and activation mechanism of different PKC isoforms.

## **Introduction**

Protein kinase C (PKC) was identified as a receptor of phorbol esters by Yasutomi Nishizuka and colleagues at the National Institute of Basic Biology in Japan and Peter Blumberg and colleagues at the National Cancer Institute in USA in the early of 1980s (Castagna et al., 1982; Leach et al., 1983). Phorbol esters are natural products which had long been known as cancer-promoting agents but the molecular targets of these natural products remained unknown until these discoveries. These discoveries brought PKC to the forefront of the cancer research field and consecutive cloning of many structurally related PKC isoforms disclosed a family of protein kinases. PKC is conserved in eukaryotes from yeast to human (Kazi et al., 2008; Mellor and Parker, 1998). The PKC family members are involved in the signal transduction events of several critical pathways including cell proliferation, differentiation and apoptosis (Mackay and Twelves, 2007). Despite three decades of extensive investigation since discovery of PKC as a phorbol esters receptor, there is only limited knowledge on isoform-specific PKC substrates and their relationship to these events. Here we discuss progress in the field of PKC biochemistry including structure, activation mechanism and regulation.

## **PKC family members**

PKC represents a family of 10 protein serine/threonine kinases which is encoded by nine

genes. PKC isoforms are members of AGC group kinase which can be broadly subdivided into three subfamilies considering their domain structure and cofactors requirement. Classical or conventional PKC isoforms are regulated by phospholipids, diacylglycerol (DAG) and calcium that include PKC $\alpha$ , PKC $\beta$ 2 and its transcription variant PKC $\beta$ 1, and PKC $\gamma$ . PKC $\delta$ , PKC $\epsilon$ , PKC $\eta$  and PKC $\theta$  are known as novel PKC isoforms which are regulated by phospholipids and DAG. PKC $\zeta$  and PKC $\iota$  are categorized as atypical PKC isoforms which are independent to DAG and calcium, but can be regulated by phospholipids. PKC proteins contain a poorly conserved amino-terminal regulatory domain and a highly conserved carboxy-terminal catalytic domain (Fig. 1).

### **PKC regulatory domain**

The PKC regulatory domain contains several regulatory regions such as pseudosubstrate region, protein kinase C homology 1 (C1) domain, protein kinase C homology 2 (C2) domain and PB1 domain. This domain is the target of lipid second messengers such as DAG and other phorbol esters. Although the 3D structure of the intact regulatory domain of PKC isoforms has not been determined yet, the crystal or solution structure of individual domains of several PKC isoforms has been resolved and the function of each of these domains has been established by extensive biochemical analysis.

*Pseudosubstrate region:* In the late 1980s House and Kemp first proposed that PKC isoforms contain a pseudosubstrate region when they identified 17 amino acid residues near the N-terminal of regulatory domain as a potent PKC substrate agonist (House and Kemp, 1987). They also found that a single alanine to serine mutation in this region changes this peptide to the potent PKC substrate. A study with an antibody against this sequence put further evidence that the pseudosubstrate region is responsible for maintaining the enzyme in an inactive state (Makowske and Rosen, 1989). A conserved arginine residue in this region was shown to be important for the high affinity binding with the active site (House and Kemp, 1990). Thus the activity of PKC isoforms is regulated by pseudosubstrate region, which blocks the substrate binding site of the enzyme in absence of agonists.

*C1 domain:* Classical and novel PKC isoforms localize to the membrane in response to increased DAG level resulting in activation of these isoforms. Membrane localization is fabricated by the direct binding of DAG to the C1 domain. The C1 domain is a zinc-containing motif of 50-51 amino acid residues. This domain is also known as cysteine-rich domain. C1 domain is found as a tandem repeat in classical and novel PKC isoforms (Fig. 1) referred to as C1a and C1b domains. Each domain has a conserved motif of cysteine and histidine residues (HX<sub>12</sub>CX<sub>2</sub>CX<sub>13</sub>-



<sub>14</sub>CX<sub>2</sub>CX<sub>4</sub>HX<sub>2</sub>CX<sub>7</sub>C). These residues create the coordination sites for two zinc ions. Classical and novel C1 domains exhibit higher affinity for phorbol esters, which are mimics to DAG. Conversely, the atypical C1 domain includes only a C1a domain and does not bind to DAG or phorbol esters. The crystal structure of PKC $\delta$ -C1b (Zhang et al., 1995) and the solution structure of PKC $\gamma$ -C1b (Xu et al., 1997) have been resolved. C1b domain is composed of five  $\beta$ -strands and one  $\alpha$ -helix (Xu et al., 1997; Zhang et al., 1995). The top third of the C1 domain is completely devoid of charged groups, while the middle third is mostly composed of positively charged side chains. Two  $\beta$ -strands form a narrow hydrophilic groove and four rings of the phorbol ester insert themselves into the groove. Three phorbol oxygens form five hydrogen bonds with two  $\beta$ -strands of the domain. The ligand covers the hydrophilic binding site of the groove so that the large part of the domain displays a flanking hydrophobic surface. This binding does not produce a significant conformational change within this domain (Zhang et al., 1995). Thus, membrane targeting is achieved by altering the nature of the protein surface rather than by changing protein conformation. One study suggests that C1 domains exhibit differential affinity for DAG and the C1b domain is the major domain for DAG binding (Szallasi et al., 1996). However, exactly how C1 domains respond differentially to the DAG remain unclear. Availability of 3D structure information of C1a domain would be useful to understand this issue.

*C2 domain:* The C2 domain was discovered as a conserved sequence motif in the classical PKC isoforms that consists of about 120 amino acid residues. The C2 domain is also present in all novel PKC isoforms. Classical C2 domains interact with phospholipid membranes in a  $\text{Ca}^{2+}$  dependent manner. The conserved aspartate residues are critical for this multiple  $\text{Ca}^{2+}$  ions binding (Corbalan-Garcia et al., 1999; Medkova and Cho, 1998). In contrast, novel C2 domains lack conserved aspartate residues and interact with acidic phospholipids in a  $\text{Ca}^{2+}$  independent manner (Corbalan-Garcia et al., 2003). Despite binding to phospholipids, the novel C2 domain has been characterized as phosphotyrosine binding domain that exhibited binding with diverse tyrosine phosphorylated proteins such as CDCP1 and PKD1 (Benes et al., 2005; Doppler and Storz, 2007). High-resolution crystal structures have been determined for the C2 domain of PKC $\alpha$  (Guerrero-Valero et al., 2009; Verdaguer et al., 1999), PKC $\beta$  (Sutton and Sprang, 1998), PKC $\gamma$  (Pike et al., 2007), PKC $\delta$  (Pappa et al., 1998), PKC $\epsilon$  (Ochoa et al., 2001) and PKC $\eta$  (Littler et al., 2006). These structures show that the C2 domain shares a common fold of conserved eight anti-parallel  $\beta$ -strands.  $\beta$ -strands are connected by variable surface loops. N-terminal region and surface loops are mostly variable among all these C2 domain structures. In classical PKC isoforms, three loops at the top of the  $\beta$ -strands provide all the residues which participate in calcium ions coordination. These three loops are referred to as CBR1 (calcium binding region), CBR2 and CBR3 (Fig. 2A). CBR1 corresponds to the  $\beta 2$  and  $\beta 3$  connection

loop which is conserved in all classical PKC-C2 (Fig. 2A), while it exhibits a large difference to novel PKC-C2 domains. CRB1 is replaced by loop1 ( $\beta$ 1-  $\beta$ 2) in novel PKC-C2 (Fig. 2B). Among all the PKC-C2 domains, the CRB3 structure ( $\beta$ 6- $\beta$ 7) is highly conserved that corresponds to novel PKC-C2 loop3 ( $\beta$ 5- $\beta$ 6). In contrast, the structure of the connecting loops at the end of the  $\beta$ -strand opposite the CRB is poorly conserved among the PKC-C2 domains.

The PKC $\beta$ -C2 domain coordinates with three calcium ions which are bonded through carboxylate groups from side chain and main chain atoms of CBR1 and CBR3, where CBR2 plays a supportive role (Sutton and Sprang, 1998). Three calcium ions binding sites were defined as site II, III and IV (Sutton and Sprang, 1998). Another classical PKC-C2 domain, the PKC $\alpha$ -C2 domain coordinates with two calcium ions (site II and III), while site IV was found to be occupied by one water molecule (Verdaguer et al., 1999). The structure of phospholipid bound PKC-C2-Ca<sup>2+</sup> complex has also been resolved and this complex does not undergo significant conformational change upon phospholipid binding (Verdaguer et al., 1999). The C2 domain of PKC $\delta$  shares considerable sequence similarity with that of PKC $\theta$ . In contrast the PKC $\delta$ -C2 domain displays less than 20% sequence similarity with PKC $\epsilon$ -C2 and PKC $\eta$ -C2 domains. PKC $\delta$ -C2 domain also shows large structural differences with PKC $\epsilon$ -C2 and PKC $\eta$ -C2 domains. These differences include the presence in the PKC $\delta$ -C2 domain structure of a helix, between strands  $\beta$ 6- $\beta$ 7 and of a protruding  $\beta$  hairpin (Ochoa et al., 2001). Loops connecting the  $\beta$ -strand

exhibit considerable variations within the novel PKC-C2 domains. Loop1 is the most variable and contains one  $\alpha$ -helix near the N-terminal connection of PKC $\epsilon$ -C2 and PKC $\eta$ -C2 domains. In contrast, no  $\alpha$ -helices are found in loop1 of the PKC $\delta$ -C2 domain or in the CRB1 of other classical PKC-C2 domains. Loop1 and loop3 correspond to the Ca<sup>2+</sup> binding sites in classical PKC-C2 domain. These loops have shown to be essential for the interaction between the novel PKC-C2 domain and the phosphatidic acid (Ochoa et al., 2001). Moreover, recently the PKC $\delta$ -C2 domain has been characterized as phosphotyrosine binding domain that exhibited binding with diverse tyrosine phosphorylated proteins such as CDCP1 and PKD1 (Benes et al., 2005; Doppler and Storz, 2007).

*PB1 domain:* The PB1 domain is a protein interaction domain present in atypical PKC isoforms, adaptor and scaffold proteins as well as other kinases such as MEKK2, MEKK3 and MEK5 (Moscat et al., 2006). The PB1 domain is conserved in animals, fungi, amoebas, and plants that participates in diverse biological processes (Sumimoto et al., 2007). Crystallographic and NMR experiments have established the 3D structure of PKC $\iota$ -PB1 domain (Hirano et al., 2004; Hirano et al., 2005). The PB1 domain contains two  $\alpha$ -helices and a mixed  $\beta$ -sheet which contains five  $\beta$ -strands. This domain extends about 80 amino acid residues and binds to other PB1 domain containing proteins (Moscat et al., 2006).

## **PKC catalytic domain**

PKC isoforms phosphorylate the substrate proteins on serine and threonine residues, usually in the context of a basic sequence (Newton, 2001) and catalytic domain alone is sufficient to complete this process. A bacterially expressed PKC $\theta$  catalytic domain was reported to be phosphorylated. The catalytic domain of PKC isoforms shows considerable (more than 60%) sequence similarity within in the family. Initially the structure of the catalytic domain of PKC isoform was determined by homology modeling based on the solved structure of PKA (Orr and Newton, 1994). PKA exhibits 40% of sequence similarity with PKC within the kinase domain. Recently the 3D structure of catalytic domain of several PKC isoforms such as PKC $\beta$ 2 (Grotsky et al., 2006), PKC $\theta$  (Xu et al., 2004) and PKC $\iota$  (Messerschmidt et al., 2005) has been resolved by crystallographic method.

The catalytic domain of PKC is folded into the classical bilobal fold as seen with other kinases. The smaller N-terminal lobe (N-lobe) is composed of five  $\beta$ -strands and two  $\alpha$ -helices. The C-terminal lobe (C-lobe) is larger and is predominantly helical consisting eight  $\alpha$ -helices. These two lobes are connected by a hinge-linker region. The active site cleft is built up by the ATP-binding site and the proximate peptide-substrate binding site and situated at the interface of both lobes. This site is solvent accessible. The glycine-rich phosphate-binding loop (GXGXXA)

connects two  $\beta$ -strands ( $\beta 1$ - $\beta 2$ ) of the bottom of N-lobe. The structure of the activation loop is well conserved across the PKC family with conserved threonine residue.

The C-terminal hydrophobic motif (FXXFS) is another conserved feature within the PKC family. Residues of this motif interact with the hydrophobic groove of the N-lobe. The serine residue of this motif is an autophosphorylation site. Atypical PKC isoforms have a glutamate at the site respective to serine (FXXFE). The glutamate residue of atypical PKC isoforms may act as phosphorylation mimic.

### **PKC activation**

The activation mechanism of PKC isoforms has been studied extensively. The general mechanism of PKC activation is that PKC isoforms undergo a process of maturation before the enzyme is able to become activated (Fig. 3) (Newton, 2003). Newly synthesized PKCs move to the membrane and are phosphorylated by PDK1 in the activation loop which has the docking site in the hydrophobic motif (Sonnenburg et al., 2001). Activation loop phosphorylation is followed by two ordered autophosphorylations in the turn motif and hydrophobic motif (Newton and Koshland, 1987). These three phosphorylation sites are well conserved within the entire PKC family, excluding a carboxy-terminal hydrophobic site that is replaced with a glutamic acid residue in the atypical PKC isoforms. Mutation studies suggest that the turn motif

phosphorylation precedes the phosphorylation of hydrophobic motif (Edwards et al., 1999). These phosphorylations lead to stabilization and maturation of the PKC isoforms. However, the maturation mechanism is common for the classical PKC isoforms (Newton, 2003), the regulation of the hydrophobic motif of the novel PKC isoforms is less understood. Recent studies have led to the conclusion that phosphorylation of the novel PKC $\delta$  at the hydrophobic motif is catalyzed by another kinase and PKC $\epsilon$  hydrophobic motif phosphorylation can be catalyzed by itself or by another kinase (Cenni et al., 2002; England et al., 2001; Parekh et al., 1999; Rybin et al., 2003; Ziegler et al., 1999). This maturation process results in a number of key conformational changes allowing the N-terminal pseudosubstrate region to interact with the substrate binding site, thus releases the enzyme from the membrane to the cytosol. This conformation keeps the enzyme as inactive form until activated by second messengers such as calcium and/or DAG.

### **PKC modulators**

The discovery of isoforms-selective modulators of PKC is crucial to understand the role of the individual isoforms in physiological and pathophysiological processes and to manipulate their function. PKC modulators include the small molecule PKC activators and inhibitors. The discovery of isoform specific PKC modulators is at present a largely unmet pharmacological need.

*PKC activators:* The binding of DAG to C1 domain activates classical and novel PKC isoforms and for that reason DAG analogs are widely used as PKC activators. Several DAG analog phorbol esters such as phorbol 12-myristate 13-acetate (PMA)/12-O-tetradecanoylphorbol-13-acetate (TPA), phorbol-12,13-didecanoate (PDD), phorbol-12,13-dibutyrate (PDBu) and phorbol-12,13-dibenzoate (PDBz), but not phorbol-12-tetradecanoate, phorbol-13-acetate and 4 $\alpha$ -phorbol-12,13-didecanoate had shown to activate PKC (Castagna et al., 1982; Kikkawa et al., 1983). These PKC activating phorbol esters are potent tumor promoters. Intracellularly DAG can be produced by the metabolism of phosphatidylinositol (PI), thus phosphatidylinositol-3,4-bisphosphate (Toker et al., 1994), phosphatidylinositol-4,5-bisphosphate (Berridge and Irvine, 1984) and phosphatidylinositol-3,4,5-trisphosphate (Toker et al., 1994) are also potent PKC activators. Cis-unsaturated fatty acids such as arachidonic acid, oleic acid, linoleic acid, linolenic acid, linoelaidic acid and docosahexaenoic acid, activate PKC isoforms and cooperate with DAG (Lo et al., 1994; Murakami et al., 1986; Murakami and Routtenberg, 1985; Shinomura et al., 1991). In addition, fatty acids display some selectivity for the activation of specific PKC isoforms. For example, classical PKC isoforms (Shinomura et al., 1991) and novel PKC $\epsilon$  (Koide et al., 1992) were shown to be activated by arachidonic acid, but another novel PKC isoform PKC $\delta$  was found to be inhibited by the same fatty acid (Ogita et al., 1992). PKC activators



targeting the C1 domain are unable to activate atypical PKC isoforms. A cell permeable ceramide has shown to activate PKC $\zeta$  in a dose dependent manner (Muller et al., 1995).

*PKC inhibitors:* Many compounds competent to inhibit PKC activity have been used extensively to probe a variety of biological mechanisms and as an approach to treat cancer, diabetes and autoimmune diseases. Most of them target the catalytic domain of the PKC isoforms, although some of them target the regulatory domain. Unfortunately, most of PKC inhibitors suffer from various degrees of nonspecificity, both within the PKC family itself and also towards other kinases. Many potent PKC inhibitors are less specific to the PKC isoforms and very often inhibit other kinases. Staurosporine was one of the first PKC inhibitors to be identified. It interacts with the catalytic domain of the enzyme. The catalytic domain is most conserved within all serine/threonine protein kinases, and it is now recognized that staurosporine inhibits a range of other protein kinases. No compound has been reported to be specific for only one PKC isoform. The derivatives of staurosporine and its analog bisindolylmaleimides show higher selectivity to specific PKC isoforms. Regulatory domain inhibitors show some specificity to PKC but still lack isoform specificity. Recent studies suggest that isoform-specific PKC inhibitors are potentially beneficial to the prevention or treatment of some cancers and diabetics. Ruboxistaurin (LY333531), a potent PKC $\beta$  inhibitor has been shown to reduce the development of diabetic

vascular complications in animal models (Joy et al., 2005). Two partially isoform-specific PKC inhibitors, UCN-01 and CGP41251 exhibited partial responses in the prevention of the progress of malignancies (Shen, 2003).

### **PKC phosphoregulators**

Phosphorylation is a reversible mechanism that regulates diverse cellular functions. Phosphorylation of proteins by protein kinases turns on a variety of signaling cascades that can be terminated by the protein phosphatases which dephosphorylate proteins.

*PKC kinases:* Classical and novel PKC isoforms are incapable of being activated by DAG without post-translational phosphorylations which are initiated by the activation loop phosphorylation and followed by couple of autophosphorylations in turn motif and hydrophobic motif. Evidence has mounted recently that PDK1 is the upstream kinase which directly phosphorylates the activation loop of many PKC isoforms (Table 1) (Cenni et al., 2002; Chou et al., 1998; Dutil et al., 1998; Le Good et al., 1998; Lee et al., 2005). The fact that PDK1 is the upstream kinase for all PKC isoforms has been emphasized by the further findings that, phosphorylation by PDK1 stabilizes PKC isoforms (Balendran et al., 2000) and that several PKC isoforms directly interact with PDK1 (Le Good et al., 1998). Although this is the common

mechanism that activation loop phosphorylation is mediated by PDK1, some other reports addressed that PKC $\epsilon$  is the upstream kinase for PKC $\delta$  activation loop phosphorylation (Rybin et al., 2007; Rybin et al., 2003). The turn motif and hydrophobic motif phosphorylations at serine residues are catalyzed by PKC itself (Newton, 2003) excluding PKC $\delta$  hydrophobic motif phosphorylation that is catalyzed by another PKC isoform, PKC $\zeta$  (Ziegler et al., 1999). Hydrophobic motif phosphorylation of PKC $\epsilon$  is debated. One report has suggested that PKC $\epsilon$  hydrophobic motif phosphorylation is mediated by a heterologous kinase (Parekh et al., 1999). Moreover, recently PKC $\delta$  has been identified as the PKC $\epsilon$  hydrophobic motif kinase in cardiomyocytes (Rybin et al., 2003).

Besides the serine and threonine phosphorylations, PKC isoforms are also phosphorylated in several tyrosine residues. For example PKC $\alpha$  and PKC $\beta$ 1 is phosphorylated by Syk (Kawakami et al., 2003), and PKC $\theta$  is phosphorylated by Lck (Liu et al., 2000) in tyrosine residues. PKC $\delta$  is in fact phosphorylated by various non-receptor tyrosine kinases, such as Abl, Fyn, Lck, Lyn and Src (Denning et al., 1996; Konishi et al., 2001; Sun et al., 2000; Szallasi et al., 1995). In contrast, classical PKC isoforms, such as PKC $\alpha$ , PKC $\beta$  and PKC $\gamma$ , were not phosphorylated by src or only to a very small extent (Gschwendt et al., 1994). PKC $\zeta$  has been identified to interact with Src (Seibenhener et al., 1999) and PKC $\iota$  has shown to be tyrosine phosphorylated by the same kinase (Wooten et al., 2001). Atypical PKC isoforms are likely to be

activated by tyrosine phosphorylation which leads to the membrane translocation of PKC $\zeta$  (Wooten et al., 2001). Other known protein kinases which phosphorylate PKC isoforms include casein kinase-1 (CK1) and casein kinase-2 (CK2). Rat brain PKC was shown to be phosphorylated by CK1 (Vila et al., 1989). Another report demonstrated that PKC $\beta$  was phosphorylated by rat lung CK2 and that neither PKC $\gamma$  nor PKC $\alpha$  was significantly phosphorylated by the same kinase (Tominaga et al., 1991).

*PKC phosphatases:* The dephosphorylation of proteins is catalyzed by three families of protein phosphatases. The serine/threonine phosphatase family members PP1 and PP2A are the major serine/threonine phosphatases in the cells. A heterotrimer form of PP2A dephosphorylated PKC $\alpha$  in vitro (Hansra et al., 1996) and inhibitors to PP2A have been shown to induce hyperphosphorylated forms of PKC $\alpha$ , PKC $\delta$  and PKC $\epsilon$  (Gatti and Robinson, 1997). The purified PP2A, PP2C and catalytic subunits of PP1 were able to dephosphorylate baculovirus-expressed PKC $\delta$  in vitro (Srivastava et al., 2002). Baculovirus-expressed PKC $\delta$  retain phosphorylated in T505, S643 and S662 sites. However, none of these phosphatases displayed any marked site specificity to the PKC $\delta$  phosphorylation sites, PP2A found to be more selective to the PKC $\delta$  when compared to the relative specific activities (Srivastava et al., 2002). Another study showed that treatment with tautomycin, but not okadaic acid resulted in a significant increase in basal

phosphorylation of PKC $\alpha$  and PKC $\beta$ 2 in MCF-7 cells (Kitatani et al., 2007). Tautomycin is an inhibitor for PP2A and PP1 which shows preference for PP1, but okadaic acid displays the opposite preference. This suggests that PP1 isoforms further identified as PP1 $\alpha$  and PP1 $\beta$  play a role in the control of PKC $\alpha$  and PKC $\beta$ 2 phosphorylation in MCF-7 cells (Kitatani et al., 2007). Differential dephosphorylation of the PKC $\beta$ 2 by catalytic subunits of PP1 and PP2A was explored (Dutil et al., 1994). PP1 dephosphorylates Thr500 plus Thr641 and Ser660 residues near the carboxyl terminus, yielding an inactive protein. PP2A dephosphorylates only Thr500 and Ser660 and yields a protein that can rephosphorylate itself to regain its native mobility (Keränen et al., 1995). Another study suggests that PKC isoforms interact with PP2A and retain as inactive kinase (Hansra et al., 1996). This interaction is abolished by the expression of a scaffold protein which binds to PP2A thus releasing PKC (Lee et al., 2008).

## **Conclusion**

PKCs play key roles in mechanisms that regulate cell proliferation, survival, apoptosis and cell migration. PKCs are dysregulated in many clinically important disorders such as various immune disorders, atherosclerotic and diabetic cardiovascular diseases, and malignancies. The past few years have seen the identification of new key players which regulate PKC isoforms. Current PKC activation screening methods are quite limited. Most studies have relied on measurements

of PKC protein expression, which typically correlates at best only weakly with PKC activation. Measurements of PKC translocation to membranes are quite informative but translocation studies are not that convenient to use as screens for PKC activation. Understanding the mechanisms which control PKC activities will have important outcomes for potential therapies.

## References

- Balendran, A., Hare, G.R., Kieloch, A., Williams, M.R., and Alessi, D.R. (2000). Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms. *FEBS Lett* 484: 217-223.
- Benes, C.H., Wu, N., Elia, A.E., Dharia, T., Cantley, L.C., and Soltoff, S.P. (2005). The C2 domain of PKCdelta is a phosphotyrosine binding domain. *Cell* 121: 271-280.
- Berridge, M.J., and Irvine, R.F. (1984). Inositol trisphosphate, a novel second messenger in cellular signal transduction. *Nature* 312: 315-321.
- Castagna, M., Takai, Y., Kaibuchi, K., Sano, K., Kikkawa, U., and Nishizuka, Y. (1982). Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. *J Biol Chem* 257: 7847-7851.
- Cenni, V., Doppler, H., Sonnenburg, E.D., Maraldi, N., Newton, A.C., and Toker, A. (2002). Regulation of novel protein kinase C epsilon by phosphorylation. *Biochem J* 363: 537-545.
- Chou, M.M., Hou, W., Johnson, J., Graham, L.K., Lee, M.H., Chen, C.S., Newton, A.C., Schaffhausen, B.S., and Toker, A. (1998). Regulation of protein kinase C zeta by PI 3-kinase and PDK-1. *Curr Biol* 8: 1069-1077.
- Corbalan-Garcia, S., Rodriguez-Alfaro, J.A., and Gomez-Fernandez, J.C. (1999). Determination of the calcium-binding sites of the C2 domain of protein kinase C alpha that are critical for its translocation to the plasma membrane. *Biochem J* 337 ( Pt 3): 513-521.
- Corbalan-Garcia, S., Sanchez-Carrillo, S., Garcia-Garcia, J., and Gomez-Fernandez, J.C. (2003). Characterization of the membrane binding mode of the C2 domain of PKC epsilon. *Biochemistry* 42: 11661-11668.
- Denning, M.F., Dlugosz, A.A., Threadgill, D.W., Magnuson, T., and Yuspa, S.H. (1996). Activation of the

epidermal growth factor receptor signal transduction pathway stimulates tyrosine phosphorylation of protein kinase C delta. *J Biol Chem* 271: 5325-5331.

Doppler, H., and Storz, P. (2007). A novel tyrosine phosphorylation site in protein kinase D contributes to oxidative stress-mediated activation. *J Biol Chem* 282: 31873-31881.

Dutil, E.M., Keranen, L.M., DePaoli-Roach, A.A., and Newton, A.C. (1994). In vivo regulation of protein kinase C by trans-phosphorylation followed by autophosphorylation. *J Biol Chem* 269: 29359-29362.

Dutil, E.M., Toker, A., and Newton, A.C. (1998). Regulation of conventional protein kinase C isozymes by phosphoinositide-dependent kinase 1 (PDK-1). *Curr Biol* 8: 1366-1375.

Edwards, A.S., Faux, M.C., Scott, J.D., and Newton, A.C. (1999). Carboxyl-terminal phosphorylation regulates the function and subcellular localization of protein kinase C betaII. *J Biol Chem* 274: 6461-6468.

England, K., Watson, J., Beale, G., Warner, M., Cross, J., and Rumsby, M. (2001). Signalling pathways regulating the dephosphorylation of Ser729 in the hydrophobic domain of protein kinase Cepsilon upon cell passage. *J Biol Chem* 276: 10437-10442.

Gatti, A., and Robinson, P.J. (1997). Okadaic acid interferes with phorbol-ester-mediated down-regulation of protein kinase C-alpha, C-delta and C-epsilon. *European journal of biochemistry / FEBS* 249: 92-97.

Grodsky, N., Li, Y., Bouzida, D., Love, R., Jensen, J., Nodes, B., Nonomiya, J., and Grant, S. (2006). Structure of the catalytic domain of human protein kinase C beta II complexed with a bisindolylmaleimide inhibitor. *Biochemistry* 45: 13970-13981.

Gschwendt, M., Kielbassa, K., Kittstein, W., and Marks, F. (1994). Tyrosine phosphorylation and stimulation of protein kinase C delta from porcine spleen by src in vitro. Dependence on the activated state of protein kinase C delta. *FEBS Lett* 347: 85-89.

Guerrero-Valero, M., Ferrer-Orta, C., Querol-Audi, J., Marin-Vicente, C., Fita, I., Gomez-Fernandez, J.C., Verdaguer, N., and Corbalan-Garcia, S. (2009). Structural and mechanistic insights into the association of PKCalpha-C2 domain to PtdIns(4,5)P2. *Proceedings of the National Academy of Sciences of the United States of America* 106: 6603-6607.

Hansra, G., Bornancin, F., Whelan, R., Hemmings, B.A., and Parker, P.J. (1996). 12-O-Tetradecanoylphorbol-13-acetate-induced dephosphorylation of protein kinase Calpha correlates with the presence of a membrane-associated protein phosphatase 2A heterotrimer. *J Biol Chem* 271: 32785-32788.

Hirano, Y., Yoshinaga, S., Ogura, K., Yokochi, M., Noda, Y., Sumimoto, H., and Inagaki, F. (2004). Solution structure of atypical protein kinase C PB1 domain and its mode of interaction with ZIP/p62 and MEK5. *J Biol Chem* 279: 31883-31890.

Hirano, Y., Yoshinaga, S., Takeya, R., Suzuki, N.N., Horiuchi, M., Kohjima, M., Sumimoto, H., and Inagaki, F. (2005). Structure of a cell polarity regulator, a complex between atypical PKC and Par6 PB1 domains. *J Biol Chem* 280: 9653-9661.

House, C., and Kemp, B.E. (1987). Protein kinase C contains a pseudosubstrate prototope in its regulatory domain. *Science (New York, NY)* 238: 1726-1728.

House, C., and Kemp, B.E. (1990). Protein kinase C pseudosubstrate prototope: structure-function relationships. *Cell Signal* 2: 187-190.

Joy, S.V., Scates, A.C., Bearely, S., Dar, M., Taulien, C.A., Goebel, J.A., and Cooney, M.J. (2005). Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications. *The Annals of pharmacotherapy* 39: 1693-1699.

Kawakami, Y., Kitaura, J., Yao, L., McHenry, R.W., Kawakami, Y., Newton, A.C., Kang, S., Kato, R.M., Leitges, M., Rawlings, D.J., *et al.* (2003). A Ras activation pathway dependent on Syk phosphorylation of protein kinase C. *Proceedings of the National Academy of Sciences of the United States of America* 100: 9470-9475.

Kazi, J.U., Kabir, N.N., and Soh, J.W. (2008). Bioinformatic prediction and analysis of eukaryotic protein kinases in the rat genome. *Gene* 410: 147-153.

Keranen, L.M., Dutil, E.M., and Newton, A.C. (1995). Protein kinase C is regulated in vivo by three functionally distinct phosphorylations. *Curr Biol* 5: 1394-1403.

Kikkawa, U., Takai, Y., Tanaka, Y., Miyake, R., and Nishizuka, Y. (1983). Protein kinase C as a possible receptor protein of tumor-promoting phorbol esters. *J Biol Chem* 258: 11442-11445.

Kitatani, K., Idkowiak-Baldys, J., and Hannun, Y.A. (2007). Mechanism of inhibition of sequestration of protein kinase C alpha/betaII by ceramide. Roles of ceramide-activated protein phosphatases and phosphorylation/dephosphorylation of protein kinase C alpha/betaII on threonine 638/641. *J Biol Chem* 282: 20647-20656.

Koide, H., Ogita, K., Kikkawa, U., and Nishizuka, Y. (1992). Isolation and characterization of the epsilon subspecies of protein kinase C from rat brain. *Proceedings of the National Academy of Sciences of the United States of America* 89: 1149-1153.

Konishi, H., Yamauchi, E., Taniguchi, H., Yamamoto, T., Matsuzaki, H., Takemura, Y., Ohmae, K., Kikkawa, U., and Nishizuka, Y. (2001). Phosphorylation sites of protein kinase C delta in H<sub>2</sub>O<sub>2</sub>-treated cells and its activation by tyrosine kinase in vitro. *Proceedings of the National Academy of Sciences of the United States of America* 98: 6587-6592.

Le Good, J.A., Ziegler, W.H., Parekh, D.B., Alessi, D.R., Cohen, P., and Parker, P.J. (1998). Protein kinase C isoforms controlled by phosphoinositide 3-kinase through the protein kinase PDK1. *Science* (New York, NY 281: 2042-2045.

Leach, K.L., James, M.L., and Blumberg, P.M. (1983). Characterization of a specific phorbol ester aporeceptor in mouse brain cytosol. *Proceedings of the National Academy of Sciences of the United States of America* 80: 4208-4212.

Lee, I.H., Lim, H.J., Yoon, S., Seong, J.K., Bae, D.S., Rhee, S.G., and Bae, Y.S. (2008). Ahnak protein activates PKC through dissociation of PKC-PP2A complex. *J Biol Chem*.

Lee, K.Y., D'Acquisto, F., Hayden, M.S., Shim, J.H., and Ghosh, S. (2005). PDK1 nucleates T cell receptor-induced signaling complex for NF-kappaB activation. *Science* (New York, NY 308: 114-118.



Littler, D.R., Walker, J.R., She, Y.M., Finerty, P.J., Jr., Newman, E.M., and Dhe-Paganon, S. (2006). Structure of human protein kinase C  $\epsilon$  (PKC $\epsilon$ ) C2 domain and identification of phosphorylation sites. *Biochem Biophys Res Commun* 349: 1182-1189.

Liu, Y., Witte, S., Liu, Y.C., Doyle, M., Elly, C., and Altman, A. (2000). Regulation of protein kinase C $\theta$  function during T cell activation by Lck-mediated tyrosine phosphorylation. *J Biol Chem* 275: 3603-3609.

Lo, H.H., Bartek, G.A., and Fischer, S.M. (1994). In vitro activation of mouse skin protein kinase C by fatty acids and their hydroxylated metabolites. *Lipids* 29: 547-553.

Mackay, H.J., and Twelves, C.J. (2007). Targeting the protein kinase C family: are we there yet? *Nature reviews* 7: 554-562.

Makowske, M., and Rosen, O.M. (1989). Complete activation of protein kinase C by an antipeptide antibody directed against the pseudosubstrate prototope. *J Biol Chem* 264: 16155-16159.

Medkova, M., and Cho, W. (1998). Mutagenesis of the C2 domain of protein kinase C- $\alpha$ . Differential roles of Ca<sup>2+</sup> ligands and membrane binding residues. *J Biol Chem* 273: 17544-17552.

Mellor, H., and Parker, P.J. (1998). The extended protein kinase C superfamily. *Biochem J* 332 ( Pt 2): 281-292.

Messerschmidt, A., Macieira, S., Velarde, M., Badeker, M., Benda, C., Jestel, A., Brandstetter, H., Neuefeind, T., and Blaesle, M. (2005). Crystal structure of the catalytic domain of human atypical protein kinase C- $\iota$  reveals interaction mode of phosphorylation site in turn motif. *Journal of molecular biology* 352: 918-931.

Moscat, J., Diaz-Meco, M.T., Albert, A., and Campuzano, S. (2006). Cell signaling and function organized by PB1 domain interactions. *Molecular cell* 23: 631-640.

Muller, G., Ayoub, M., Storz, P., Rennecke, J., Fabbro, D., and Pfizenmaier, K. (1995). PKC zeta is a molecular switch in signal transduction of TNF- $\alpha$ , bifunctionally regulated by ceramide and arachidonic acid. *Embo J* 14: 1961-1969.

Murakami, K., Chan, S.Y., and Routtenberg, A. (1986). Protein kinase C activation by cis-fatty acid in the absence of Ca<sup>2+</sup> and phospholipids. *J Biol Chem* 261: 15424-15429.

Murakami, K., and Routtenberg, A. (1985). Direct activation of purified protein kinase C by unsaturated fatty acids (oleate and arachidonate) in the absence of phospholipids and Ca<sup>2+</sup>. *FEBS Lett* 192: 189-193.

Newton, A.C. (2001). Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. *Chem Rev* 101: 2353-2364.

Newton, A.C. (2003). Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. *Biochem J* 370: 361-371.

Newton, A.C., and Koshland, D.E., Jr. (1987). Protein kinase C autophosphorylates by an intrapeptide reaction. *J Biol Chem* 262: 10185-10188.

Ochoa, W.F., Garcia-Garcia, J., Fita, I., Corbalan-Garcia, S., Verdaguer, N., and Gomez-Fernandez, J.C.

(2001). Structure of the C2 domain from novel protein kinase Cepsilon. A membrane binding model for Ca(2+)-independent C2 domains. *Journal of molecular biology* 311: 837-849.

Ogita, K., Miyamoto, S., Yamaguchi, K., Koide, H., Fujisawa, N., Kikkawa, U., Sahara, S., Fukami, Y., and Nishizuka, Y. (1992). Isolation and characterization of delta-subspecies of protein kinase C from rat brain. *Proceedings of the National Academy of Sciences of the United States of America* 89: 1592-1596.

Orr, J.W., and Newton, A.C. (1994). Intrapeptide regulation of protein kinase C. *J Biol Chem* 269: 8383-8387.

Pappa, H., Murray-Rust, J., Dekker, L.V., Parker, P.J., and McDonald, N.Q. (1998). Crystal structure of the C2 domain from protein kinase C-delta. *Structure* 6: 885-894.

Parekh, D., Ziegler, W., Yonezawa, K., Hara, K., and Parker, P.J. (1999). Mammalian TOR controls one of two kinase pathways acting upon nPKCdelta and nPKCepsilon. *J Biol Chem* 274: 34758-34764.

Pike, A.C.W., Amos, A., Johansson, C., Sobott, F., Savitsky, P., Berridge, G., Fedorov, O., Umeano, C., Gorrec, F., Bunkoczi, G., *et al.* (2007). Crystal Structure of C2 Domain of Protein Kinase C Gamma. Cited from Protein data bank.

Rybin, V.O., Guo, J., Gertsberg, Z., Elouardighi, H., and Steinberg, S.F. (2007). Protein kinase Cepsilon (PKCepsilon) and Src control PKCdelta activation loop phosphorylation in cardiomyocytes. *J Biol Chem* 282: 23631-23638.

Rybin, V.O., Sabri, A., Short, J., Braz, J.C., Molkentin, J.D., and Steinberg, S.F. (2003). Cross-regulation of novel protein kinase C (PKC) isoform function in cardiomyocytes. Role of PKC epsilon in activation loop phosphorylations and PKC delta in hydrophobic motif phosphorylations. *J Biol Chem* 278: 14555-14564.

Seibenhener, M.L., Roehm, J., White, W.O., Neidigh, K.B., Vandenplas, M.L., and Wooten, M.W. (1999). Identification of Src as a novel atypical protein kinase C-interacting protein. *Mol Cell Biol Res Commun* 2: 28-31.

Shen, G.X. (2003). Selective protein kinase C inhibitors and their applications. *Current drug targets* 3: 301-307.

Shinomura, T., Asaoka, Y., Oka, M., Yoshida, K., and Nishizuka, Y. (1991). Synergistic action of diacylglycerol and unsaturated fatty acid for protein kinase C activation: its possible implications. *Proceedings of the National Academy of Sciences of the United States of America* 88: 5149-5153.

Sonnenburg, E.D., Gao, T., and Newton, A.C. (2001). The phosphoinositide-dependent kinase, PDK-1, phosphorylates conventional protein kinase C isozymes by a mechanism that is independent of phosphoinositide 3-kinase. *J Biol Chem* 276: 45289-45297.

Srivastava, J., Goris, J., Dilworth, S.M., and Parker, P.J. (2002). Dephosphorylation of PKCdelta by protein phosphatase 2A and its inhibition by nucleotides. *FEBS Lett* 516: 265-269.

Sumimoto, H., Kamakura, S., and Ito, T. (2007). Structure and function of the PB1 domain, a protein interaction module conserved in animals, fungi, amoebas, and plants. *Sci STKE* 2007: re6.

Sun, X., Wu, F., Datta, R., Kharbanda, S., and Kufe, D. (2000). Interaction between protein kinase C delta and the c-Abl tyrosine kinase in the cellular response to oxidative stress. *J Biol Chem* 275: 7470-7473.

Sutton, R.B., and Sprang, S.R. (1998). Structure of the protein kinase Cbeta phospholipid-binding C2 domain complexed with Ca<sup>2+</sup>. *Structure* 6: 1395-1405.

Szallasi, Z., Bogi, K., Gohari, S., Biro, T., Acs, P., and Blumberg, P.M. (1996). Non-equivalent roles for the first and second zinc fingers of protein kinase Cdelta. Effect of their mutation on phorbol ester-induced translocation in NIH 3T3 cells. *J Biol Chem* 271: 18299-18301.

Szallasi, Z., Denning, M.F., Chang, E.Y., Rivera, J., Yuspa, S.H., Lehel, C., Olah, Z., Anderson, W.B., and Blumberg, P.M. (1995). Development of a rapid approach to identification of tyrosine phosphorylation sites: application to PKC delta phosphorylated upon activation of the high affinity receptor for IgE in rat basophilic leukemia cells. *Biochem Biophys Res Commun* 214: 888-894.

Toker, A., Meyer, M., Reddy, K.K., Falck, J.R., Aneja, R., Aneja, S., Parra, A., Burns, D.J., Ballas, L.M., and Cantley, L.C. (1994). Activation of protein kinase C family members by the novel polyphosphoinositides PtdIns-3,4-P<sub>2</sub> and PtdIns-3,4,5-P<sub>3</sub>. *J Biol Chem* 269: 32358-32367.

Tominaga, M., Kitagawa, Y., Tanaka, S., and Kishimoto, A. (1991). Phosphorylation of type II (beta) protein kinase C by casein kinase II. *Journal of biochemistry* 110: 655-660.

Verdaguer, N., Corbalan-Garcia, S., Ochoa, W.F., Fita, I., and Gomez-Fernandez, J.C. (1999). Ca(2+) bridges the C2 membrane-binding domain of protein kinase Calpha directly to phosphatidylserine. *Embo J* 18: 6329-6338.

Vila, J., Walker, J.M., Itarte, E., Weber, M.J., and Sando, J.J. (1989). Phosphorylation of protein kinase C by casein kinase-1. *FEBS Lett* 255: 205-208.

Wooten, M.W., Vandenplas, M.L., Seibenhener, M.L., Geetha, T., and Diaz-Meco, M.T. (2001). Nerve growth factor stimulates multisite tyrosine phosphorylation and activation of the atypical protein kinase C's via a src kinase pathway. *Molecular and cellular biology* 21: 8414-8427.

Xu, R.X., Pawelczyk, T., Xia, T.H., and Brown, S.C. (1997). NMR structure of a protein kinase C-gamma phorbol-binding domain and study of protein-lipid micelle interactions. *Biochemistry* 36: 10709-10717.

Xu, Z.B., Chaudhary, D., Olland, S., Wolfrom, S., Czerwinski, R., Malakian, K., Lin, L., Stahl, M.L., Joseph-McCarthy, D., Benander, C., *et al.* (2004). Catalytic domain crystal structure of protein kinase C-theta (PKCtheta). *J Biol Chem* 279: 50401-50409.

Zhang, G., Kazanietz, M.G., Blumberg, P.M., and Hurley, J.H. (1995). Crystal structure of the cys2 activator-binding domain of protein kinase C delta in complex with phorbol ester. *Cell* 81: 917-924.

Ziegler, W.H., Parekh, D.B., Le Good, J.A., Whelan, R.D., Kelly, J.J., Frech, M., Hemmings, B.A., and Parker, P.J. (1999). Rapamycin-sensitive phosphorylation of PKC on a carboxy-terminal site by an atypical PKC complex. *Curr Biol* 9: 522-529.

## **Figure Legends**

**Fig. 1.** Schematic representation of the structure of the PKC family.

**Fig. 2.** Three dimensional structures of PKC C2 domains.

**Fig. 3.** PKC activation mechanism.

**Table 1. Isoform-specific PKC kinases**

<b>Group</b>	<b>Family</b>	<b>Kinase</b>	<b>PKC</b>	<b>Reference</b>
AGC	PKB	PDK1	PKC $\alpha$ , PKC $\beta$ 2, PKC $\delta$ , PKC $\epsilon$ , PKC $\theta$ , PKC $\zeta$	(Cenni et al., 2002; Chou et al., 1998; Dutil et al., 1998; Le Good et al., 1998; Lee et al., 2005)
AGC	PKC	PKC $\delta$	PKC $\epsilon$	(Rybin et al., 2003)
AGC	PKC	PKC $\epsilon$	PKC $\delta$	(Rybin et al., 2003)
AGC	PKC	PKC $\zeta$	PKC $\delta$	(Ziegler et al., 1999)
Other	CK1	CK1	Rat brain PKC	(Vila et al., 1989)
Other	CK2	CK2	PKC $\beta$	(Tominaga et al., 1991)
TK	Abl	cAbl	PKC $\delta$	(Sun et al., 2000)
TK	Src	Fyn	PKC $\delta$	(Denning et al., 1996)
TK	Src	Lck	PKC $\delta$ , PKC $\theta$	(Konishi et al., 2001; Liu et al., 2000)
TK	Src	Lyn	PKC $\delta$	(Szallasi et al., 1995)
TK	Src	Src	PKC $\delta$ , PKC $\iota$	(Denning et al., 1996; Wooten et al., 2001)
TK	Syk	Syk	PKC $\alpha$ , PKC $\beta$ 1	(Kawakami et al., 2003)

Figure 1.




Figure 2.




Figure 3.

